PTGS2 and prostate carcinoma: In addition, PTGS2 inhibitors, a key enzyme in prostaglandin biosynthesis, resulted in decreased recurrence and mortality in patients with breast (NCT00525096, NCT02429427) and prostate cancer (NCT00316927).